Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

The total value of the deal exceeds $1bn for the first three targets, in addition to royalty payments based on net sales.

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery ...

While its heirs rank among the world’s youngest billionaires, the German drugmaker Boehringer Ingelheim is rather ancient—it was founded in 1885, and its entrepreneurial roots stretch back ...

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative™, designed to improve treatment of the interconnected ...